Volume | 40,503 |
|
|||||
News | - | ||||||
Day High | 0.41 | Low High |
|||||
Day Low | 0.375 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Frequency Therapeutics Inc | FREQ | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.39 | 0.375 | 0.41 | 0.3709 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
153 | 40,503 | $ 0.3886829 | $ 15,743 | - | 0.3258 - 5.59 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
12:39:37 | 14 | $ 0.3901 | USD |
Frequency Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
14.52M | 36.52M | - | 0 | -81.58M | -2.23 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Frequency Therapeutics News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical FREQ Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.3811 | 0.4299 | 0.35 | 0.3762303 | 61,082 | 0.0164 | 4.3% |
1 Month | 0.49 | 0.49 | 0.35 | 0.4202693 | 92,271 | -0.0925 | -18.88% |
3 Months | 0.37 | 0.8101 | 0.34 | 0.681349 | 1,845,730 | 0.0275 | 7.43% |
6 Months | 0.4514 | 0.8101 | 0.3258 | 0.6542323 | 950,765 | -0.0539 | -11.94% |
1 Year | 1.86 | 5.59 | 0.3258 | 0.9611359 | 713,227 | -1.46 | -78.63% |
3 Years | 19.86 | 58.37 | 0.3258 | 6.24 | 565,989 | -19.46 | -98.0% |
5 Years | 11.20 | 58.37 | 0.3258 | 7.47 | 466,293 | -10.80 | -96.45% |
Frequency Therapeutics Description
Frequency Therapeutics Inc is a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused by degenerative diseases. Its Progenitor Cell Activation approach uses combinations of molecules to activate progenitor cells within the body to create functional tissue. Its product candidate FX-322 is being developed for treating sensorineural hearing loss. |